Castle Biosciences(us:CSTL)

    27.53

    +1.62%

    Updated on 2024-12-22

    Open:26.58
    Close:27.53
    High:27.99
    Low:26.58
    Pre Close:27.09
    Volume:382571.00
    Amount:10.46M
    Turnover:1.37%
    Shares:28.01M
    MarketCap:771.04M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-301772515045190.76%315469
    2024-03-311662492130290.34%195471
    2023-12-311692381136286.87%355663
    2023-09-301482308456185.85%225255
    2023-06-301602296202085.73%186858
    2023-03-311612198667982.39%156353
    2022-12-311802272575585.58%235182
    2022-09-301712172042282.43%245761
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Blackrock Inc.25956879.41%31248813.69%
    2024-03-31Wasatch Advisors Lp25510889.25%-39863-1.54%
    2024-03-31Granahan Investment Management, Llc16272245.90%-539247-24.89%
    2024-03-31Principal Financial Group Inc15324725.56%-53201-3.35%
    2024-03-31Vanguard Group Inc14941765.42%326952.24%
    2024-03-31Bellevue Group Ag12200854.42%-12293-1.00%
    2024-03-31Portolan Capital Management, Llc10434103.78%31475743.20%
    2024-03-31Deerfield Management Company, L.P. (Series C)9280173.36%-37411-3.88%
    2024-03-31Dimensional Fund Advisors Lp7492592.72%8537712.86%
    2024-03-31Soleus Capital Management, L.P.7254572.63%6994572690.22%

    About

    Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
    Address:505 South Friendswood Drive,Suite 401

    Market Movers